ArticleMedical oncology (Northwood, London, England)2025
Revolutionizing early HCC detection: groundbreaking validation of the HCC-check index for small tumors in Egyptian patients using CLIP and BCLC staging systems.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predicting the prognosis of hepatocellular carcinoma after curative resection using a nomogram based on the ratio of prealbumin to platelet distribution width.Journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is often associated with better treatment options for small asymptomatic tumors if HCC is caught early. A year ago, the "Technology in Cancer Research and Treatment" Journal published a report on the highly sensitive HCC-Check for the early diagnosis of HCC. Here, we examine and confirm the applicability of HCC-Check in 486 liver-diseased patients with earlier stages of HCC based on two widely used Cancer of the Liver Italian Program (CLIP) and Barcelona Clinic Liver Cancer (BCLC) staging systems for the identification of small tumors. Our results showed that HCC-Check produced 0.90 AUC with 78.26% sensitivity and 83.89% specificity, when used to distinguish small HCCs from cirrhotic patients. Our findings showed that HCC-Check increased with disease progression according to the CLIP and BCLC systems, producing significant (p < 0.0001) Spearman correlation coefficients of 0.633 and 0.458, respectively. HCC-Check yielded 0.85 (0.78-0.92) AUC, 66.67% (47.19-82.71) sensitivity, and 83.89% (77.69-88.94) specificity for identifying CLIP (0-1) while producing 0.87 (0.79-0.94) AUC, 65% (40.78-84.61) sensitivity, and 83.89% (77.69-88.94) specificity for identifying BCLC A. Additionally, HCC-Check yielded 0.90 (0.83-0.97) AUC, 78.26% (56.30-92.54) sensitivity, and 83.89% (77.69-88.94) specificity for discriminating small tumors < 3 cm. Simplified HCC-Check still competes with HCC-Check, providing 0.89 (0.83-0.95) AUC with 73.91% (51.60-89.77) sensitivity and 82.51% (76.22-87.72) specificity for identifying small-sized HCC. All these results were superior to those obtained by AFP. In conclusion, the study findings support that HCC-Check and its simplified version could be a useful tool for early detection of HCC, aiding definitive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.